Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral SclerosisLoreto Martínez‐González, Ana Martı́nez, Claudia Gonzalo‐Consuegra et al.|International Journal of Molecular Sciences|2021Cited by 67
Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS PatientsDiana Posa, Ángeles Martín‐Requero, Ana Martı́nez et al.|Molecular Neurobiology|2018Cited by 36
Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP‐43‐related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)Gabriela Liseth Vaca-Altamirano, Ángeles Martín‐Requero, Loreto Martínez‐González et al.|Journal of Neurochemistry|2020Cited by 30
Molecular Alterations in Sporadic and SOD1-ALS Immortalized Lymphocytes: Towards a Personalized TherapyIsabel Lastres‐Becker, Ángeles Martín‐Requero, Gracia Porras et al.|International Journal of Molecular Sciences|2021Cited by 26
Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral SclerosisOlmo Martín-Cámara, J. Carlos Menéndez, Marina Arribas et al.|Journal of Medicinal Chemistry|2022Cited by 22